KDM3A在乳腺癌中的表达及临床意义

摘要
图/表
参考文献(18)
相关文章 (15)

全文: PDF (0 KB) HTML (35 KB)
输出: BibTeX | EndNote (RIS)

摘要目的研究组蛋白去甲基化酶KDM3A在乳腺癌及正常乳腺组织中的表达差异以及其与临床病理特征的关系。方法用于免疫组化的乳腺癌组织及正常乳腺组织均来源于沈阳医学院附属中心医院，收集2013～2015年的乳腺癌石蜡标本，患者均为女性。采用免疫组化SP法检测100例乳腺癌、30例正常乳腺组织中KDM3A的表达情况。分析KDM3A的表达与患者年龄、雌激素受体（ER）、孕激素受体（PR）、肿瘤分期、瘤体大小以及淋巴结转移等临床病理特征的关系。结果KDM3A在乳腺癌组织中的阳性率为89.0%（89/100），在正常乳腺组织中的阳性率为66.7%（20/30），KDM3A在乳腺癌中的表达高于正常乳腺组织，差异有统计学意义（P＜0.05）；KDM3A的表达与瘤体的大小以及ER表达有相关性。结论乳腺癌组织中KDM3A呈高表达，且与肿瘤瘤体的大小以及ER表达有相关性，提示KDM3A可能在ER阳性乳腺癌中发挥促进乳腺癌生长及增殖作用。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	孙东源
	张铭阳
	王岚
	吴怡

关键词 ：乳腺癌, 去甲基化酶, KDM3A, 免疫组化

Abstract：ObjectiveTo study the difference of the expression of histone demethylation enzyme KDM3A in breast cancer tissue and normal breast tissue and its relationship with clinicopathological characteristics.MethodsThe breast cancer tissues and normal breast tissues used in immunohistochemistry were derived from the Central Hospital Affiliated to Shenyang Medical College.The paraffin specimens of breast cancer were collected from 2013 to 2015,all of which were women.The expression of KDM3A in 100 cases of breast cancers and 30 cases of normal breast tissues was detected by using immunohistochemical SP method.The relationship between the expression of KDM3A and the clinicopathological features of patients′age,estrogen receptor　(ER),progesterone receptor　(PR),tumor stage,tumor size and lymph node metastasis were analyzed.ResultsThe positive rate of KDM3A in breast cancer tissues was 89.0%(89/100),and the positive rate of KDM3A in normal breast tissue was 66.7%　(20/30).The expression of KDM3A in breast cancer was higher than that of normal breast tissue,with statistically significant difference　(P＜0.05).The expression of KDM3A was related to the size of the tumor and the expression of ER.ConclusionThe high expression of KDM3A in breast cancer tissue is related to the size of tumor and the expression of ER,suggesting that KDM3A may play a role in promoting the growth and proliferation of breast cancer in ER-positive breast cancers.

Key words： Breast cancer Demethylation enzyme KDM3A Immunohistochemistry

基金资助:国家级大学生创新创业训练计划项目（20151016 4000004）；辽宁省教育厅科学技术研究项目（L2013403）；辽宁省大学生创新创业训练计划项目（甲类20151164）；沈阳医学院大学生科研项目（20150804）

通讯作者: 吴怡，女，博士研究生，讲师，研究方向：核受体介导基因转录调控的表观遗传机制

引用本文:

孙东源;张铭阳;王岚;吴怡. KDM3A在乳腺癌中的表达及临床意义[J]. 中国当代医药, 2018, 25(18): 4-06.
SUN Dong-yuan;ZHANG Ming-yang;WANG Lan;WU Yi. Expression of KDM3A in breast cancer and its clinical significance. 中国当代医药, 2018, 25(18): 4-06.

链接本文:

http://dangdaiyiyao.com/CN/ 或 http://dangdaiyiyao.com/CN/Y2018/V25/I18/4

[1]	令狐锐霞，司文，李莹，等.3846例乳腺癌流行病学及临床病理学分析[J].解放军医学院学报，2015，36（10）：1017-1021.
[2]	苏亚梅，杨鑫，彭伟伟，等.云南省乳腺癌患者临床流行病学特征分析[J].中外医疗，2015，20（2）：99-102.
[3]	Fan L，Kathrin SW，Jun JL，et al.Breast cancer in China[J].Lancet Oncol，2014，15（7）：e279-e289.
[4]	贺立彩，朱真锋，郑倩倩，等.ACTL8的表达与乳腺癌临床病理特征及预后的关系[J].中国病理生理杂志，2016，32（6）：1138-1141，1146.
[5]	郭晓强，马克世.组蛋白去甲基化酶JMJD家族的特点和功能[J].生命的化学，2008，28（3）：275-278.
[6]	Wade MA，Jones D，Wilson L，et al.The histone demethylase enzyme KDM3A is a key estrogen receptor regulator in breast cancer[J].Nucleic Acids Res，2015，43（1）：196-207.
[7]	Okada Y，Tateishi K，Zhang Y，et al.Histone demethylase JHDM2A is involved in male infertility and obesity[J].J Androl，2010，31（1）：75-78.
[8]	Krieg AJ，Rankin EB，Chan D，et al.Regulation of the histone demethylase JMJD1A by hypoxia-inducible factor1α enhances hypoxic gene expression and tumor growth[J].Mol Cell Biol，2010，30（1）：344-353.
[9]	Garcia-Bassets I，Kwon YS，Telese F，et al.Histone methylation-dependent mechanisms impose ligand dependency for gene activation by nuclear receptors[J].Cell，2007，128（3）：505-518.
[10]	Suikki HE，Kujala PM，Tammela TL，et al.Genetic alterations and changes in expression of histone demethylases in prostate cancer[J].Prostate，2010，70（8）：889-898.
[11]	Wilson S，Fan L，Sahgal N，et al.The histone demethylase KDM3A regulates the transcriptional program of the androgen receptor in prostate cancer cells[J].Oncotarget，2017，8（18）：30328-30343.
[12]	Li Y，Yang W，Wu B，et al.KDM3A promotes inhibitory cytokines secretion by participating in TLR4 regulation of Foxp 3 transcription in lung adenocarcinoma cells[J].Oncol Lett，2017，13（5）：3529-3537.
[13]	Sechler M，Parrish JK，Birks DK，et al.The histone demethylase KDM3A，and its downstream target MCAM，promote Ewing Sarcoma cell migration and metastasis[J].Oncogene，2017，36（29）：4150-4160.
[14]	Wan W，Peng K，Li M，et al.Histone demethylase JMJD1A promotes urinary bladder cancer progression by enhancing glycolysis through coactivation of hypoxia inducible factor 1[J].Oncogene.2017，36（27）：3868-3877.
[15]	Uemura M，Yamamoto H，Takemasa I，et al.Jumonji domain containing 1A is a novel prognostic marker for colorectal cancer：in vivo identification from hypoxic tumor cells[J].Clin Cancer Res，2010，16（18）：4636-4646.
[16]	Guo X，Shi M，Sun L，et al.The expression of histone demethylase JMJD1A in renal cell carcinoma[J].Neoplasma，2011，58（2）：153-157.
[17]	Ramadoss S，Sen S，Ramachandran I，et al.Lysine-specific demethylase KDM3A regulates ovarian cancer stemness and chemoresistance[J].Oncogene，2017，36（11）：1537-1545.
[18]	Zhan M，Wen F，Liu L，et al.JMJD1A promotes tumorigenesis and forms a feedback loop with EZH2/let-7c in NSCLC cells[J].Tumour Biol，2016，37（8）：11237-11247.